Alekseeva G G, Iukhlova N A
Probl Endokrinol (Mosk). 1979 May-Jun;25(3):13-8.
Glycemia, growth hormone level and urinary catecholamine excretion were studied in 182 patients suffering from insulin-dependent diabetes mellitus during insulin therapy alone, and in 33 during treatment with insulin plus alpha- and beta-adrenoblockers. Under the effect of alpha-adrenoblockers glycemia proved to fall in the insulin-dependent patients, without increasing the insulin dose. The STH level diminished in these patients under the effect of alpha-adrenoblockers, even when glycemia persisted at the same level. But beta-adrenoblockers aggravated decompensation and the STH level remained unchanged. alpha and beta-adrenoblockers decreased the urinary adrenaline excretion and elevated noradrenaline, dophamine and DOPA excretion, irrespective of blood glycemia. The authors recommend the use of alpha-adrenoblockers to prevent the necessity of a considerable elevation of insulin doses during compensation in patients with the insulin-resistant form of diabetes mellitus. beta-adrenoblockers are not recommended in diabetes mellitus.
对182例仅接受胰岛素治疗的胰岛素依赖型糖尿病患者以及33例接受胰岛素加α和β肾上腺素能阻滞剂治疗的患者进行了血糖、生长激素水平和尿儿茶酚胺排泄的研究。在α肾上腺素能阻滞剂的作用下,胰岛素依赖型患者的血糖下降,且无需增加胰岛素剂量。在α肾上腺素能阻滞剂的作用下,这些患者的生长激素水平降低,即使血糖维持在相同水平。但β肾上腺素能阻滞剂会加重失代偿,生长激素水平保持不变。无论血糖水平如何,α和β肾上腺素能阻滞剂均可降低尿肾上腺素排泄,升高去甲肾上腺素、多巴胺和多巴排泄。作者建议使用α肾上腺素能阻滞剂,以避免胰岛素抵抗型糖尿病患者在代偿期大幅增加胰岛素剂量。糖尿病患者不建议使用β肾上腺素能阻滞剂。